Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilapladib in Atherosclerosis
NCT00695305Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing Placebo with Rilapladib (2 arms). Primary endpoints: Safety from AE reporting, vital signs, clinical labs, ECGs, slit lamp eye exams and electron microscopy of peripheral blood lymphocytes at 12 weeks, LP-PLA2 activity at 12 weeks and 1 more. Started Nov 2008; status: completed.
02
Drugs
rilapladib
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00695305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695305.